Back to Authors

Heldebrant, Michael P.

Mayo Clinic

Sidney Kimmel Cancer Center

Citations 3

Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine
Loegering, David A., Powell, Heather L., Flatten, Karen S., Arlander, Sonnet J.H., Dai, Nga T., Heldebrant, Michael P., Vroman, Benjamin T., Karp, Judith E. , Eyck, Cynthia J. Ten, Erlichman, Charles , Karnitz, Larry M., Mesa, Ruben A. , Smith, B. Douglas , Eyck, Cynthia Ten, Kaufmann, Scott H.

Blood | March 23, 2005 | Volume: 106 | Issue: 1 | Pages: 318-327

10.1182/blood-2004-09-3523 Get It

Previous studies demonstrated that ataxia telangiectasia mutated– and Rad3-related (ATR) kinase and its downstream target checkpoint kinase 1 (Chk1) facilitate survival of cells treated with nucleoside analogs and other replication inhibitors. Recent results also demonstrated that Chk1 is depleted when cells are treated with heat shock protein 90 (Hsp90) inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG). The present study examined the effects of 17-AAG and its major metabolite, 17-aminogeldanamycin (17-AG), on Chk1 levels and cellular responses to cytarabine in human acute myelogenous leukemia (AML) cell lines and clinical isolates. Cytarabine, at concentrations as low as 30 nM, caused activating phosphorylation of Chk1, loss of the phosphatase Cdc25A, and S-phase slowing. Conversely, treatment with 100 to 300 nM 17-AAG for 24 hours caused Chk1 depletion that was accompanied by diminished cytarabine-induced S-phase accumulation, decreased Cdc25A degradation, and enhanced cytotoxicity as measured by inhibition of colony formation and induction of apoptosis. Additional studies demonstrated that small inhibitory RNA (siRNA) depletion of Chk1 also sensitized cells to cytarabine, whereas disruption of the phosphatidylinositol 3-kinase (PI3k) signaling pathway, which is also blocked by Hsp90 inhibition, did not. Collectively, these results suggest that treatment with 17-AAG might represent a means of reversing checkpoint-mediated cytarabine resistance in AML.
Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?
Loprinzi, Charles L. , Sargent, Daniel J. , Thomé, Stephan D. , Haller, Daniel G. , Benedetti, Jacqueline, Francini, Guido, Shepherd, Lois E. , Seitz, Jean François, Labianca, Roberto , Chen, Wei , Cha, Stephen S., Heldebrant, Michael P., Goldberg, Richard M. , Gill, Sharlene , Alberts, Steven R. , Cha, Stephen S., Sargent, Daniel J

Journal of Clinical Oncology | April 5, 2004 | Volume: 22 | Issue: 10 | Pages: 1797-1806

10.1200/jco.2004.09.059 Get It

Purpose Although it is well-established that fluorouracil- (FU-) based adjuvant therapy improves survival for patients with resected high-risk colon cancer, the magnitude of adjuvant therapy benefit across specific subgroups and for individual patients has been uncertain. Patients and Methods Using a pooled data set of 3,302 patients with stage II and III colon cancer from seven randomized trials comparing FU + leucovorin or FU + levamisole to surgery alone, we performed an analysis based on a Cox proportional hazards regression model. Treatment, age, sex, tumor location, T stage, nodal status, and grade were tested for both prognostic and predictive significance. Model derived estimates of 5-year disease-free survival and overall survival (OS) for surgery alone and surgery plus FU-based therapy were calculated for a range of patient subsets. Results Nodal status, T stage, and grade were the only prognostic factors independently significant for both disease-free survival and OS. Age was significant only for OS. In a multivariate analysis, adjuvant therapy showed a beneficial treatment effect across all subsets. Treatment benefits were consistent across sex, location, age, T-stage, and grade. A significant stage by treatment interaction was present, with treatment benefiting stage III patients to a greater degree than stage II patients. Conclusion Patients with high-risk resected colon cancer obtain benefit from FU-based therapy across subsets of age, sex, location, T stage, nodal status, and grade. Model estimates of survival stratified by T stage, nodal status, grade, and age are available at http://www.mayoclinic.com/calcs . This information may improve patients' and physicians' understanding of the potential benefits of adjuvant therapy.
Microtubule destabilization and nuclear entry are sequential steps leading to toxicity in Huntington's disease
Trushina, Eugenia , Heldebrant, Michael P., Pérez-Terzic, Carmen, Bortolon, Ryan, Kovtun, Irina V. , Badger, John D., Estévez, Álvaro G. , Windebank, Anthony J. , Dyer, Roy B. , Yao, Janet , McMurray, Cynthia T. , Terzic, André , Trushina, Eugenia

Proceedings of the National Academy of Sciences | October 14, 2003 | Volume: 100 | Issue: 21 | Pages: 12171-12176

10.1073/pnas.2034961100 Get It

There has been a longstanding debate regarding the role of proteolysis in Huntington's disease. The toxic peptide theory posits that N-terminal cleavage fragments of mutant Huntington's disease protein [mutant huntingtin (mhtt)] enter the nucleus to cause transcriptional dysfunction. However, recent data suggest a second model in which proteolysis of full-length mhtt is inhibited. Importantly, the two competing theories differ with respect to subcellular distribution of mhtt at initiation of toxicity: nuclear if cleaved and cytoplasmic in the absence of cleavage. Using quantitative single-cell analysis and time-lapse imaging, we show here that transcriptional dysfunction is “downstream” of cytoplasmic dysfunction. Primary and reversible toxic events involve destabilization of microtubules mediated by full-length mhtt before cleavage. Restoration of microtubule structure by taxol inhibits nuclear entry and increases cell survival.